Smoking and rheumatoid arthritis
K Chang, SM Yang, SH Kim, KH Han, SJ Park… - International journal of …, 2014 - mdpi.com
Rheumatoid arthritis (RA) is a chronic inflammatory disease caused by both genetic and
environmental factors. Smoking has been implicated as one of the most important extrinsic …
environmental factors. Smoking has been implicated as one of the most important extrinsic …
The impact of cigarette smoking on risk of rheumatoid arthritis: a narrative review
Y Ishikawa, C Terao - Cells, 2020 - mdpi.com
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation
and subsequent proliferation of synovial tissues, which eventually leads to cartilage and …
and subsequent proliferation of synovial tissues, which eventually leads to cartilage and …
[PDF][PDF] Clinical significance of soluble interleukin-2 receptor measurement in immune-mediated diseases
WA Dik, M Heron - Neth J Med, 2020 - njmonline.nl
ABSTRACT A soluble form of the interleukin-2 receptor (sIL-2R) is secreted upon T-cell
activation. Increased blood levels of sIL-2R occur in a variety of immunological diseases …
activation. Increased blood levels of sIL-2R occur in a variety of immunological diseases …
Serum soluble interleukin 2 receptor α in human cancer of adults and children: a review
E Bien, A Balcerska - Biomarkers, 2008 - Taylor & Francis
Cancer growth and development is associated with the stimulation of the innate immune
system, including enhanced interleukin 2 receptor (IL-2R) expression in immune cells and …
system, including enhanced interleukin 2 receptor (IL-2R) expression in immune cells and …
[HTML][HTML] Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis
H Guo, L Li, B Liu, P Lu, Z Cao, X Ji, G Ouyang… - International …, 2023 - Elsevier
In recent years, difficult-to-treat rheumatoid arthritis (D2T RA) has attracted significant
attention from rheumatologists due to its poor treatment response and the persistent …
attention from rheumatologists due to its poor treatment response and the persistent …
Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis
Aims: This study aimed to examine the efficacy of a nanocarrier (polyethyleneimine [PEI]-
superparamagnetic iron oxide nanoparticle [SPIO]), composed of a core of iron oxide and a …
superparamagnetic iron oxide nanoparticle [SPIO]), composed of a core of iron oxide and a …
CD25 as an immune regulatory molecule expressed on myeloid dendritic cells
J Driesen, A Popov, JL Schultze - Immunobiology, 2008 - Elsevier
CD25 (α-chain of IL-2 receptor) on dendritic cells (DC) has been previously regarded as an
activation marker. DC that concomitantly express surface CD25 and co-stimulatory …
activation marker. DC that concomitantly express surface CD25 and co-stimulatory …
Anti-TNF antibodies: lessons from the past, roadmap for the future
DJ Shealy, S Visvanathan - Therapeutic Antibodies, 2008 - Springer
Tumor necrosis factor alpha (TNF) is an important cell-signaling component of the immune
system. Since its discovery over 20 years ago, much has been learned about its functions …
system. Since its discovery over 20 years ago, much has been learned about its functions …
Factors influencing serum concentrations of soluble interleukin-2 receptor: a general adult population study
V Alende-Castro, M Alonso-Sampedro… - All Life, 2023 - Taylor & Francis
Introduction: Measuring soluble interleukin-2 receptor (sIL-2R) might be useful for diagnosis
and monitoring of immune-mediated diseases. The study investigated factors associated …
and monitoring of immune-mediated diseases. The study investigated factors associated …
Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis
MJH Coenen, EJM Toonen, H Scheffer… - …, 2007 - Taylor & Francis
TNF-blocking strategies are widely used in the treatment of rheumatoid arthritis (RA). Three
anti-TNF agents are registered for use in RA: etanercept, infliximab and adalimumab …
anti-TNF agents are registered for use in RA: etanercept, infliximab and adalimumab …